

Arcadia Biosciences Inc

21:33 14 Oct 2020

Calyxt appoints agribusiness veteran Sarah Reiter as vice president of business development

Calyxt Inc (NASDAQ:CLXT), a plant-based technology company based in Minnesota, announced Wednesday that it has appointed Sarah Reiter as vice president of business development.

Reiter will drive new business opportunities at Calyxt to support the company's recently announced go-to-market strategies.

Reiter is a plant-based technology and agribusiness leader focused on establishing world-class partnerships and value chains that lead to the successful commercialization of emerging technologies for start-up, early-stage and Fortune 500 companies. She will apply her expertise in international business development, acquisitions and product portfolio management in agribusiness to develop, refine and implement the overall commercial strategy for Calyxt's future products, including the prioritization of markets, customers and product types.

READ: Calyxt hits 5 times revenue growth in 2Q results as plant sales expand

"Calyxt continues to build momentum with our go-to-market strategies, and the addition of Sarah to the leadership team will help us to optimize and execute on these strategies going forward," said CEO Jim Blome in a statement.

"Her proven success in the plant-based innovation sector is an ideal match for our technology, positioning us to be even more responsive to evolving consumer, sustainability and marketplace demands."

With more than 25 years of expertise in agribusiness, Reiter most recently served as the chief commercial officer of Arcadia Biosciences Inc (NASDAQ:RKDA) where she led the company's commercial and product portfolio strategies and sales to consumer-packaged goods companies globally.

Prior to Arcadia Biosciences, she served as the CEO of Stockton U.S.A. with oversight of the US division of the global multinational bio-ag company from inception to initial sales. She earned her Master's Certificate in Business Analysis from the Villanova School of Continuing Education and her Bachelor's degree from the University of California, Davis.


Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 3.07

Market Cap: \$41.16 m

1 Year Share Price Graph



January 2020 July 2020 January 2021

Share Information

Code: RKDA

Listing: NASDAQ

52 week	High	Low
	6.47	2.35

Sector: Agribusiness

Website: arcadiabio.com

Company Synopsis:

Arcadia Biosciences is a consumer-driven agricultural technology company that develops and commercializes high-value food ingredients, nutritional oils and products that help meet consumer demand for a healthier diet. Our GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Arcadia Biosciences Inc named herein, including the promotion by the Company of Arcadia Biosciences Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).